145 related articles for article (PubMed ID: 29219668)
21. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
Poncelet AC; de Caestecker MP; Schnaper HW
Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
[TBL] [Abstract][Full Text] [Related]
22. Expression of TGF-beta1, TbetaRII and Smad4 in colorectal carcinoma.
Xu WQ; Jiang XC; Zheng L; Yu YY; Tang JM
Exp Mol Pathol; 2007 Jun; 82(3):284-91. PubMed ID: 17289018
[TBL] [Abstract][Full Text] [Related]
23. Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Qiu W; Schönleben F; Li X; Su GH
Cancer Lett; 2007 Jan; 245(1-2):163-70. PubMed ID: 16478646
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer.
Kleeff J; Friess H; Simon P; Susmallian S; Büchler P; Zimmermann A; Büchler MW; Korc M
Dig Dis Sci; 1999 Sep; 44(9):1793-802. PubMed ID: 10505717
[TBL] [Abstract][Full Text] [Related]
25. Pregnancy-specific glycoprotein 9 (PSG9), a driver for colorectal cancer, enhances angiogenesis via activation of SMAD4.
Yang L; Hu S; Tan J; Zhang X; Yuan W; Wang Q; Xu L; Liu J; Liu Z; Jia Y; Huang X
Oncotarget; 2016 Sep; 7(38):61562-61574. PubMed ID: 27528036
[TBL] [Abstract][Full Text] [Related]
26. TGF-β1 pathway affects the protein expression of many signaling pathways, markers of liver cancer stem cells, cytokeratins, and TERT in liver cancer HepG2 cells.
Wang XH; Liu MN; Sun X; Xu CH; Liu J; Chen J; Xu RL; Li BX
Tumour Biol; 2016 Mar; 37(3):3675-81. PubMed ID: 26462837
[TBL] [Abstract][Full Text] [Related]
27. Low expression of B-Cell-Associated protein 31 is associated with unfavorable prognosis in human colorectal cancer.
Ma C; Jin RM; Chen KJ; Hao T; Li BS; Zhao DH; Jiang H
Pathol Res Pract; 2018 May; 214(5):661-666. PubMed ID: 29653744
[TBL] [Abstract][Full Text] [Related]
28. TGF-beta signaling in colon cancer cells.
Li F; Cao Y; Townsend CM; Ko TC
World J Surg; 2005 Mar; 29(3):306-11. PubMed ID: 15711891
[TBL] [Abstract][Full Text] [Related]
29. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.
Lee JL; Roh SA; Kim CW; Kwon YH; Ha YJ; Kim SK; Kim SY; Cho DH; Kim YS; Kim JC
World J Gastroenterol; 2019 Mar; 25(11):1341-1354. PubMed ID: 30918427
[TBL] [Abstract][Full Text] [Related]
30. Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma.
Báez A; Cantor A; Fonseca S; Marcos-Martinez M; Mathews LA; Muro-Cacho CA; Muñoz-Antonia T
Clin Cancer Res; 2005 May; 11(9):3191-7. PubMed ID: 15867212
[TBL] [Abstract][Full Text] [Related]
31. The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma.
Ji F; Fu SJ; Shen SL; Zhang LJ; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP
BMC Cancer; 2015 Mar; 15():116. PubMed ID: 25880619
[TBL] [Abstract][Full Text] [Related]
32. Transforming Growth Factor-β Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment.
Itatani Y; Kawada K; Sakai Y
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31756952
[TBL] [Abstract][Full Text] [Related]
33. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression.
Swallow CJ; Partridge EA; Macmillan JC; Tajirian T; DiGuglielmo GM; Hay K; Szweras M; Jahnen-Dechent W; Wrana JL; Redston M; Gallinger S; Dennis JW
Cancer Res; 2004 Sep; 64(18):6402-9. PubMed ID: 15374947
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of Smad2 reveals its concerted action with Smad4 in regulating TGF-beta-mediated epidermal homeostasis.
Ito Y; Sarkar P; Mi Q; Wu N; Bringas P; Liu Y; Reddy S; Maxson R; Deng C; Chai Y
Dev Biol; 2001 Aug; 236(1):181-94. PubMed ID: 11456453
[TBL] [Abstract][Full Text] [Related]
35. Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling.
Torbenson M; Marinopoulos S; Dang DT; Choti M; Ashfaq R; Maitra A; Boitnott J; Wilentz RE
Hum Pathol; 2002 Sep; 33(9):871-6. PubMed ID: 12378510
[TBL] [Abstract][Full Text] [Related]
36. Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
BMC Cancer; 2019 May; 19(1):421. PubMed ID: 31060539
[TBL] [Abstract][Full Text] [Related]
37. The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function.
Zhang Y; Musci T; Derynck R
Curr Biol; 1997 Apr; 7(4):270-6. PubMed ID: 9094310
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between Expression of TGF-β1, Smad2, Smad4 and Prognosis
of Patients with Resected Non-small Cell Lung Cancer].
Xie M; He C; Wei S
Zhongguo Fei Ai Za Zhi; 2015 Sep; 18(9):543-8. PubMed ID: 26383977
[TBL] [Abstract][Full Text] [Related]
39. Focal adhesion molecule Kindlin-1 mediates activation of TGF-β signaling by interacting with TGF-βRI, SARA and Smad3 in colorectal cancer cells.
Kong J; Du J; Wang Y; Yang M; Gao J; Wei X; Fang W; Zhan J; Zhang H
Oncotarget; 2016 Nov; 7(46):76224-76237. PubMed ID: 27776350
[TBL] [Abstract][Full Text] [Related]
40. TGF-β1, but not bone morphogenetic proteins, activates Smad1/5 pathway in primary human macrophages and induces expression of proatherogenic genes.
Nurgazieva D; Mickley A; Moganti K; Ming W; Ovsyi I; Popova A; Sachindra ; Awad K; Wang N; Bieback K; Goerdt S; Kzhyshkowska J; Gratchev A
J Immunol; 2015 Jan; 194(2):709-18. PubMed ID: 25505291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
